Observations of Maternal Creatine Levels Throughout Gestation in Low Risk Pregnant Women. The Creatine and Pregnancy Outcomes (CPO) Study.
Not Applicable
Completed
- Conditions
- PregnancyDiet and NutritionReproductive Health and Childbirth - Normal pregnancyDiet and Nutrition - Other diet and nutrition disorders
- Registration Number
- ACTRN12618001558213
- Lead Sponsor
- Dr Stacey Ellery
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Female
- Target Recruitment
- 224
Inclusion Criteria
Pregnant women attending low risk antenatal clinics and planning to birth at Monash Health, Melbourne, Victoria
Exclusion Criteria
Women who have a known significant pre-existing major medical condition or who have been assessed as high risk or have a multiple pregnancy
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Concentrations of creatine in maternal blood throughout pregnancy. [10-20 weeks, 21-23 weeks, 24-27 weeks, 28-32 weeks, 33-36 weeks & Birth. ];Concentrations of creatine in maternal urine throughout pregnancy [10-20 weeks, 21-23 weeks, 24-27 weeks, 28-32 weeks, 33-36 weeks & Birth. ];Concentrations of creatine in cord blood. [Birth]
- Secondary Outcome Measures
Name Time Method Dietary nutrient intake of women whilst pregnant (composite of macro and micro nutrient), based on data collected from Cancer Council's Dietary Questionaire for Epidemiological studies and 24 hour food recalls, analysed using Foodworks 8 (Xyris software). [10-20 weeks, 21-23 weeks, 24-27 weeks, 28-32 weeks, 33-36 weeks & Birth.]; Placental creatine content, measured from a punch biopsy from placental tissue, using LC-MS/MS[ Birth];Placental creatine synthesis at term (composite of mRNA and protein expression of synthesising enzymes AGAT and GAMT). mRNA will be measured using RT-qPCR. Protein measurements will be conducted using western blot. [Birth]